What are the differences between rosuvastatin and pravastatin in terms of potency, metabolism, dosing, and safety profile?

Rosuvastatin vs Pravastatin: Key Differences

Rosuvastatin is significantly more potent than pravastatin, requiring approximately 8 times lower doses to achieve equivalent LDL-C reduction, but carries a higher risk of new-onset diabetes and metabolic adverse effects. 1

Potency and LDL-C Lowering Efficacy

Rosuvastatin demonstrates substantially greater lipid-lowering potency compared to pravastatin:

• Rosuvastatin 10 mg achieves approximately 52% LDL-C reduction, while pravastatin 40 mg achieves only 24% reduction 2
• Rosuvastatin is classified as high-intensity statin therapy (≥50% LDL-C reduction) at 20-40 mg doses, whereas pravastatin is classified as moderate-intensity (30-49% reduction) at 40-80 mg or low-intensity (<30% reduction) at 10-20 mg 3
• Direct comparative studies show rosuvastatin is at least 8 times more potent than pravastatin on a milligram-to-milligram basis 1
• In head-to-head trials, rosuvastatin 10 mg reduced LDL-C by 29% compared to pravastatin 20 mg reducing LDL-C by 20.3% 4

Metabolism and Pharmacokinetics

The two statins have fundamentally different metabolic pathways:

• Pravastatin undergoes non-CYP450 metabolism, making it less susceptible to drug-drug interactions mediated by cytochrome P450 enzymes 5
• Rosuvastatin undergoes minimal CYP2C9 metabolism, also reducing CYP-mediated drug interaction risk 5
• Pravastatin has 20% renal excretion (highest among statins), while rosuvastatin has 10% renal excretion 5
• Rosuvastatin has a significantly longer half-life (19 hours) compared to pravastatin (1.8 hours), allowing for more sustained drug exposure 5, 6
• Both drugs are relatively hydrophilic (water-soluble), which contributes to their greater hepatoselectivity and reduced peripheral tissue uptake compared to lipophilic statins 6

Drug Transport and Hepatic Uptake

Both statins rely on active hepatic uptake, but rosuvastatin demonstrates superior efficiency:

• Both are substrates for OATP1B1 and OATP1B3 transporters for hepatic uptake 5
• Rosuvastatin has approximately half the Km (9.17 μM) compared to pravastatin (16.5 μM), indicating greater affinity for hepatic uptake transporters 7
• Rosuvastatin demonstrates significantly higher Vmax and carrier-mediated uptake clearance than pravastatin, with a contribution ratio of 0.903 versus 0.654 for pravastatin 7
• This translates to more efficient hepatic extraction and greater liver selectivity for rosuvastatin 7

Safety Profile and Metabolic Effects

Critical differences exist in metabolic safety profiles between these agents:

Glucose Metabolism and Diabetes Risk

• Rosuvastatin significantly increases fasting insulin (+28%), HbA1c (+1%), and decreases insulin sensitivity (-2% by QUICKI) and adiponectin levels (-9%) 8
• Pravastatin demonstrates opposite effects: decreases fasting insulin (-8%), HbA1c (-1%), while increasing adiponectin (+36%) and insulin sensitivity (+3%) 8
• In the LODESTAR trial, rosuvastatin was associated with a 39% higher risk of new-onset diabetes requiring antidiabetic medications (7.2% vs 5.3%; HR 1.39,95% CI 1.03-1.87) compared to atorvastatin 9
• In experimental diabetic models, pravastatin at 20 mg/kg ameliorated adverse changes in liver enzymes and reduced fasting blood glucose, while rosuvastatin at 20 mg/kg worsened glycemic control and reduced liver glycogen content 10

Other Safety Considerations

• Rosuvastatin was associated with 66% higher risk of cataract surgery (2.5% vs 1.5%; HR 1.66,95% CI 1.07-2.58) in the LODESTAR trial 9
• Renal function considerations: Atorvastatin showed the safest renal profile (10.9% new-onset microalbuminuria), followed by rosuvastatin (14.3%), then pravastatin (26.6%) in diabetic patients 4
• Both statins have low risk of CYP450-mediated drug interactions, making them safer choices when multiple medications are prescribed 5
• Muscle toxicity risk is generally low for both agents, though pravastatin's lack of CYP metabolism may provide additional safety margin 5

Clinical Dosing Equivalence

When substituting between these agents:

• Rosuvastatin 5 mg ≈ Pravastatin 40 mg for approximate LDL-C lowering equivalence 3, 2
• Rosuvastatin 10 mg ≈ Pravastatin 80 mg (though pravastatin 80 mg is rarely used) 3, 2
• For patients requiring high-intensity statin therapy (≥50% LDL-C reduction), rosuvastatin 20-40 mg is appropriate, while pravastatin cannot reliably achieve this threshold 3

Clinical Pitfalls and Caveats

Important considerations when choosing between these agents:

• For patients with diabetes or prediabetes, pravastatin may be preferable due to its favorable metabolic profile and lack of adverse effects on glucose metabolism 8, 10
• For patients requiring aggressive LDL-C lowering (>50%), rosuvastatin is necessary as pravastatin cannot achieve high-intensity statin therapy targets 3
• In patients with significant renal impairment, both require dose adjustment, but pravastatin's higher renal excretion (20%) necessitates more careful monitoring 5
• When drug-drug interactions are a concern, both are excellent choices due to minimal CYP450 metabolism 5
• The superior potency of rosuvastatin comes at the cost of increased diabetes risk, which must be weighed against cardiovascular benefits 8, 9